Kamada stock set to recover from EMA withdrawal shock, presents good investment opportunity $KMDA

By |July 20th, 2017|Monthly Investment Ideas|

Kamada Ltd. ($KMDA) stock showed strong performance as it gained over 42 percent in the past 12 months. However, the actual performance of the stock was overshadowed by a steep decline of 25 percent in the past one month. The decline was mainly due to the company’s withdrawal of European [...]

Premarket Biotech Digest – $TTOO gets CE Mark, $QURE receives new patent, $GILD receives FDA approval

By |July 19th, 2017|Digest|

Vertex Pharmaceuticals ($VRTX) reported positive mid-stage results from three different triple combination regimens in cystic fibrosis (CF) patients suffering from one F508del mutation and one minimal function mutation. The data from the Phase 2 study showed mean absolute improvements in lung function of 9.7% [...]

Valeant sells off business unit to reduce debt pile, pushing stock higher $VRX

By |July 18th, 2017|Monthly Investment Ideas|

Valeant Pharmaceuticals International Inc. ($VRX) stock gained over 19 percent this year so far. After a prolonged period of downward spiral, the stock is showing signs of revival. The change is mainly on account of the company taking strategic decision to boost its core business and trim its debt pile. [...]

Premarket Biotech Digest – $CTIC receives EMA validation, $AMGN seeks to add data, $EBS inks new deal

By |July 17th, 2017|Digest|

Biocept ($BIOC) stock showed strong movements as the company announced that its new liquid biopsy test for progesterone receptor (PR), a biomarker in the blood for breast cancer, is now commercially available. Veena Singh, M.D., Biocept's Senior Vice President and Medical Director said, “With [...]

Premarket Biotech Digest – $FMI inks new deal, $SGMI gets Fast Track designation, $ANTM files a suit

By |July 14th, 2017|Digest|

Foundation Medicine Inc. (NASDAQ:FMI) announced inking a new deal with Kura Oncology for supporting enrollment in its its Phase 2 clinical trial evaluating farnesylation inhibitor tipifarnib in patients with treatment-resistant HRAS-mutant squamous cell carcinoma of the head and neck (SCCHN). Under the terms of [...]

Tesaro stock to gain from first mover PARP inhibitors ovarian cancer drug $TSRO

By |July 13th, 2017|Monthly Investment Ideas|

Tesaro Inc. ($TSRO) stock has gained over 55 percent in the past 12 months. The stock price has kept up with the operational success of the company as Tesaro received significant drug approvals in the US and Europe. The stock is also expected to keep up the momentum as the [...]

Premarket Biotech Digest – $SVRA reports positive interim results, $VBIV to start new studies, $KOOL inks a new agreement

By |July 12th, 2017|Digest|

Verastem Inc. ($VSTM) stock continues its upward trajectory as it gained further 16 percent in its previous trading session. The investors seem positive about the company’s prospects regarding its blood cancer candidate Duvelisib. The company recently reported long-term follow-up data from a Phase 2 [...]

AcelRx banks on DSUVIA, offers robust short term investment opportunity

By |July 11th, 2017|Monthly Investment Ideas|

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX), after suffering a setback with its Zalviso drug, is looking to hear some positive news. AcelRx is scheduled to announce its Phase 3 study data later this month. The company had received the CRL pertaining the drug in July, 2014. The CRL asked the company to [...]

Premarket Biotech Digest – $CELG inks new deal, $LLY gets favorable ruling, $ALR modifies deal

By |July 10th, 2017|Monthly Investment Ideas|

Celgene Corporation ($CELG) announced that it has agreed to acquire a stake in BeiGene. The deal has valued BeiGene stock at $4.58 apiece. The company will buy 5.9 percent of the total stock, which would be 32.7 million shares. BeiGene is set to receive [...]

Ocular stock looks solid ahead of a key FDA decision $OCUL

By |July 7th, 2017|Monthly Investment Ideas|

Ocular Therapeutix Inc. ($OCUL) is a biopharmaceutical company and focuses on developing treatments for ocular conditions using its hydrogel platform technology. The company is currently on the verge of a major catalyst as it awaits the FDA decision for its Dextenza treatment due on July 19th, which is its lead [...]

Premarket Biotech Digest – $PRAN announces new publication, $ALXN inks a new deal, $PRTA starts new study

By |July 6th, 2017|Digest|

Prana Biotechnology Limited ($PRAN) reported that its article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease” was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications. The company stock soared on the news. The [...]

Anika Therapeutics offers a long term growth opportunity with robust pipeline $ANIK

By |July 5th, 2017|Monthly Investment Ideas|

Anika Therapeutics Inc. ($ANIK) is an orthopedic medicines company and it employs its hyaluronic acid (HA) technology for developing various treatments. The company offers a good potential for medium to long term investment as it has a strong and diversified product pipeline. Apart from the pipeline, it also has robust [...]

Premarket Biotech Digest – $SKLN provides update, $BMRN files application, $GSK inks new deal

By |July 3rd, 2017|Digest|

Centene ($CNC) announced that it will launch its health insurance marketplace product in Missouri in 2018. The company intends to distribute its Ambetter product in 40 counties. 25 of these counties were not expected to have any other insurers available for enrollment. The company [...]

Premarket Biotech Digest – $PFE receives EU approval, $ALKS announces positive results, $SRNE receives FDA approval

By |June 30th, 2017|Digest|

Myovant Sciences Ltd ($MYOV) announced initiating  a Phase 3 clinical program consisting of two international clinical trials, SPIRIT 1 and SPIRIT 2. The trials will evaluate the efficacy and safety of relugolix in women with endometriosis-associated pain. SPIRIT 1 and SPIRIT 2 are randomized, double-blind, [...]

Pacific Biosciences looks promising as it targets low competition plant genome segment $PACB

By |June 29th, 2017|Monthly Investment Ideas|

Pacific Biosciences of California Inc. ($PACB) is engaged in developing and manufacturing sequencing systems for solving genetic issues. The company recently developed a new sequencing system for the maize genome, which is expected to pave the way for complex crop as well as livestock genomes. The company used its proprietary [...]

Premarket Biotech Digest – $SPNC acquired by Philips, $DSKX settles litigation, $CEMI inks new deal

By |June 28th, 2017|Digest|

ADMA Biologics Inc. ($ADMA) stock shot up as the company announced it is well on its way to get an acquired biologics manufacturing facility back on track. The company CEO Adam Grossman wrote a letter to shareholders stating that Boca Raton, Florida site is [...]

Omeros Corporation: Multiple drug candidates make for attractive long term investment $OMER

By |June 27th, 2017|Monthly Investment Ideas|

Omeros Corporation ($OMER) is a biopharma company which is engaged in developing small molecule and protein therapeutics for different conditions. The company emerges as a strong investment target with its diverse drug pipeline. Once the company’s strong performance in these trials is factored in, the stock becomes even more attractive [...]

Premarket Biotech Digest – $PTLA receives FDA approval, $KPTI offers updates, $NVO starts new study

By |June 26th, 2017|Digest|

Idera Pharmaceuticals Inc. ($IDRA) received a positive boost as the FDA designated its Phase 2-stage IMO-2125 an Orphan Drug for the treatment of Stages IIB to IV melanoma. The  Orphan Drug status in the U.S. offers an additional seven-year period of market exclusivity for [...]

Premarket Biotech Digest – $DMPI receives IRB nod, $PFE slapped with CRL, $PRTO strikes new deal

By |June 23rd, 2017|Digest|

VistaGen ($VTGN) stock shot up as the company announced the results  two Phase 1 studies of AV-101, a potential candidate for the non-opioid treatment of neuropathic pain. The data showed AV-101 was safe and well-tolerated.  The company said that the data, along with positive [...]

Corbus moves lead candidate to Phase 3 study, offers good investment deal $CRBP

By |June 22nd, 2017|Monthly Investment Ideas|

Corbus Pharmaceuticals Holdings ($CRBP) is engaged in controversial yet lucrative medical cannabis sector. The company is currently working to develop  anabasum, an endocannabinoid-mimetic drug to treat inflammatory and fibrotic diseases. It recently announced the results from the previously completed Phase 2 clinical study of the lead drug candidate for the [...]

s2Member®